IV 

109TH CONGRESS 

2D SESSION H. RES. 844 

Congratulating the International AIDS Vaccine Initiative on ten years of 

significant achievement in the search for an HIV/AIDS vaccine, and 

for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 25, 2006 

Mr. ENGEL (for himself, Mr. KING of New York, Mr. LANTOS, Mr. BERMAN, 

Mr. BROWN of Ohio, Mr. WEXLER, Ms. LEE, Mr. CROWLEY, Ms. 

MCCOLLUM of Minnesota, Mr. CARNAHAN, Mr. SWEENEY, Mr. PALLONE, 

Mr. WAXMAN, Mrs. CAPPS, Mr. NADLER, Mr. MCNULTY, Mrs. 

MALONEY, Mr. TOWNS, Mr. HIGGINS, Mr. HINOJOSA, Ms. BORDALLO, 

Mr. MCDERMOTT, Ms. MILLENDER-MCDONALD, Mr. MCGOVERN, Mr. 

CUMMINGS, Mrs. MCCARTHY, Mr. RUSH, Ms. JACKSON-LEE of Texas, 

Mr. DOYLE, and Ms. BALDWIN) submitted the following resolution; which 

was referred to the Committee on International Relations 

RESOLUTION 

Congratulating the International AIDS Vaccine Initiative on 

ten years of significant achievement in the search for 

an HIV/AIDS vaccine, and for other purposes. 

Whereas HIV/AIDS has killed over 25,000,000 people worldwide and poses a serious threat to the economic and political stability of the countries hit hardest by this terrible 

epidemic; 

Whereas the International AIDS Vaccine Initiative (IAVI) 

was founded in 1996 as a public-private partnership with 

a mission to ensure the development of safe, effective, acVerDate Aug 31 2005 00:40 May 31, 2006 Jkt 049200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6300 E:\BILLS\HR844.IH HR844

jcorcoran on PROD1PC62 with BILLS
2 

•HRES 844 IH

cessible, preventive HIV/AIDS vaccines for use throughout the world, with a particular focus on developing countries, where the need is most urgent; 

Whereas ten years ago, insufficient attention and resources 

were devoted to the need for, and advantages of, a vaccine to bring an end to this disease; 

Whereas the International AIDS Vaccine Initiative’s research 

and policy programs have galvanized scientific efforts and 

substantially increased financial and political support for 

this vital effort; 

Whereas since its founding, the International AIDS Vaccine 

Initiative has advanced six vaccine candidates from concept to clinical trials, targeting the subtypes of HIV circulating in the developing world—a record matched only 

by one large pharmaceutical company; 

Whereas today, the majority of newly designed HIV/AIDS 

vaccine candidates are focused on preventing HIV/AIDS 

in the developing world, in large part due to the efforts 

of the International AIDS Vaccine Initiative; 

Whereas ten years ago only a few developing countries had 

participated in HIV/AIDS vaccine trials, but today several countries in sub-Saharan Africa and Asia are actively participating in HIV/AIDS vaccine trials, a reflection of the International AIDS Vaccine Initiative’s activism and commitment to working collaboratively with developing country partners; 

Whereas the model of the International AIDS Vaccine Initiative, which closely links clinical trial site investigators to 

product developers, has resulted in the first HIV/AIDS 

vaccine trials being conducted in Kenya, Rwanda, and 

India, as well as trials in Uganda and South Africa; 


jcorcoran on PROD1PC62 with BILLS
3 

•HRES 844 IH

Whereas the International AIDS Vaccine Initiative is committed to ensuring that vaccines will be accessible as soon 

as possible to those who need them most urgently; 

Whereas the International AIDS Vaccine Initiative is a 

founding member of the Global HIV/AIDS Vaccine Enterprise, recognized by the G8 as an important actor in 

the quest for a vaccine; 

Whereas the International AIDS Vaccine Initiative is an affiliated member of the National Institutes of Health’s 

Partnership for AIDS Vaccine Evaluation and is hosting 

NIH trials at International AIDS Vaccine Initiative sites 

in Africa; 

Whereas the International AIDS Vaccine Initiative’s inclusive 

approach unites scientists, academics, nonprofit organizations, and governments from the north and south, including communities of faith, communities of color, and many 

others, in an effort to develop a vaccine to stop global 

HIV infection rates of 14,000 a day; 

Whereas the International AIDS Vaccine Initiative established a Core Clinical Immunology Laboratory and a network of field laboratories in the developing world to facilitate HIV/AIDS vaccine evaluation; 

Whereas the International AIDS Vaccine Initiative’s Core 

Clinical Immunology Laboratory was the first Good Clinical Laboratory Practices (GCLP) accredited laboratory 

in the world to assess HIV/AIDS vaccines, and the International AIDS Vaccine Initiative’s laboratory in Uganda 

was the first to receive such accreditation in Africa; 

Whereas the International AIDS Vaccine Initiative has pioneered a successful business model as the first global 


jcorcoran on PROD1PC62 with BILLS
4 

•HRES 844 IH

health public-private partnership, building a bridge between research and product development; and 

Whereas the International AIDS Vaccine Initiative established a ground-breaking Neutralizing Antibody Consortium to address one of the key scientific challenges to 

vaccine design: Now, therefore, be it 

1 Resolved, That the House of Representatives— 

2 (1) congratulates the International AIDS Vac3 cine Initiative on ten years of significant achieve4 ment in the search for an HIV/AIDS vaccine; 

5 (2) recognizes the role of the International 

6 AIDS Vaccine Initiative in raising awareness and in7 creasing financial and political support for this im8 portant cause; 

9 (3) admires the commitment of the Inter10 national AIDS Vaccine Initiative to collaborating 

11 with developing country researchers, governments, 

12 and civil society in the common goal of finding a 

13 vaccine; 

14 (4) expresses support for the continued success 

15 of the International AIDS Vaccine Initiative; and 

16 (5) directs the Clerk of the House of Represent17 atives to transmit an enrolled copy of this resolution 

18 to the International AIDS Vaccine Initiative. 

Æ 


jcorcoran on PROD1PC62 with BILLS